170 related articles for article (PubMed ID: 37087941)
41. Expression of insulin-like growth-factor-1 receptor (IGF-1R) in peripheral nerve sheath tumors in neurofibromatosis type 1.
Friedrich RE; Keiner D; Hagel C
Anticancer Res; 2007; 27(4A):2085-90. PubMed ID: 17649826
[TBL] [Abstract][Full Text] [Related]
42. Genetic and phenotypic characterization of tumor cells derived from malignant peripheral nerve sheath tumors of neurofibromatosis type 1 patients.
Frahm S; Mautner VF; Brems H; Legius E; Debiec-Rychter M; Friedrich RE; Knöfel WT; Peiper M; Kluwe L
Neurobiol Dis; 2004 Jun; 16(1):85-91. PubMed ID: 15207265
[TBL] [Abstract][Full Text] [Related]
43. p53 modulates kinase inhibitor resistance and lineage plasticity in NF1-related MPNSTs.
Grit JL; McGee LE; Tovar EA; Essenburg CJ; Wolfrum E; Beddows I; Williams K; Sheridan RTC; Schipper JL; Adams M; Arumugam M; Vander Woude T; Gurunathan S; Field JM; Wulfkuhle J; Petricoin EF; Graveel CR; Steensma MR
Oncogene; 2024 May; 43(19):1411-1430. PubMed ID: 38480916
[TBL] [Abstract][Full Text] [Related]
44. Survival outcomes of malignant peripheral nerve sheath tumors (MPNSTs) with and without neurofibromatosis type I (NF1): a meta-analysis.
Lim Z; Gu TY; Tai BC; Puhaindran ME
World J Surg Oncol; 2024 Jan; 22(1):14. PubMed ID: 38191386
[TBL] [Abstract][Full Text] [Related]
45. International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis.
Ferner RE; Gutmann DH
Cancer Res; 2002 Mar; 62(5):1573-7. PubMed ID: 11894862
[TBL] [Abstract][Full Text] [Related]
46. Giant malignant nerve sheath tumor of lumbosacral plexus with intraspinal extension in a child with neurofibromatosis type 1.
Pratap A; Nepal P; Agrawal A; Singh MP; Pandey SR
Pediatr Neurosurg; 2007; 43(5):410-3. PubMed ID: 17786009
[TBL] [Abstract][Full Text] [Related]
47. New Frontiers in Therapy of Peripheral Nerve Sheath Tumors in Patients With Neurofibromatosis Type 1: Latest Evidence and Clinical Implications.
Marjanska A; Galazka P; Wysocki M; Styczynski J
Anticancer Res; 2020 Apr; 40(4):1817-1831. PubMed ID: 32234870
[TBL] [Abstract][Full Text] [Related]
48. The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1.
Barkan B; Starinsky S; Friedman E; Stein R; Kloog Y
Clin Cancer Res; 2006 Sep; 12(18):5533-42. PubMed ID: 17000690
[TBL] [Abstract][Full Text] [Related]
49. NF1
Dodd RD; Lee CL; Overton T; Huang W; Eward WC; Luo L; Ma Y; Ingram DR; Torres KE; Cardona DM; Lazar AJ; Kirsch DG
Cancer Res; 2017 Aug; 77(16):4486-4497. PubMed ID: 28646022
[TBL] [Abstract][Full Text] [Related]
50. Neurofibromatosis-associated malignant peripheral nerve sheath tumors in children have a worse prognosis: A nationwide cohort study.
Martin E; Coert JH; Flucke UE; Slooff WM; van de Sande MAJ; van Noesel MM; Grünhagen DJ; Wijnen MHWA; Verhoef C
Pediatr Blood Cancer; 2020 Apr; 67(4):e28138. PubMed ID: 31889416
[TBL] [Abstract][Full Text] [Related]
51. STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.
Somatilaka BN; Madana L; Sadek A; Chen Z; Chandrasekaran S; McKay RM; Le LQ
J Clin Invest; 2024 Mar; 134(10):. PubMed ID: 38502231
[TBL] [Abstract][Full Text] [Related]
52. A retroperitoneal NF1-independent malignant peripheral nerve sheath tumor with elevated serum CA125: case report and discussion.
Yan B; Meng X; Shi B; Shi J; Qin Z; Wei P
J Neurooncol; 2012 Aug; 109(1):205-11. PubMed ID: 22528792
[TBL] [Abstract][Full Text] [Related]
53. Clinical characteristics and NF1 gene mutation analysis of three successive generations in three different Indian families with neurofibromatosis type 1 and peripheral nerve sheath tumours.
Prasad BCM; Chandra VVR; Sudarsan A; Kumar PS; Sarma PVGK
J Clin Neurosci; 2018 Jul; 53():62-68. PubMed ID: 29680440
[TBL] [Abstract][Full Text] [Related]
54. Malignant peripheral nerve sheath tumors (MPNST) in NF1-affected children.
Friedrich RE; Hartmann M; Mautner VF
Anticancer Res; 2007; 27(4A):1957-60. PubMed ID: 17649804
[TBL] [Abstract][Full Text] [Related]
55. Survival meta-analyses for >1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1.
Kolberg M; Høland M; Agesen TH; Brekke HR; Liestøl K; Hall KS; Mertens F; Picci P; Smeland S; Lothe RA
Neuro Oncol; 2013 Feb; 15(2):135-47. PubMed ID: 23161774
[TBL] [Abstract][Full Text] [Related]
56. Prognostic significance of AKT/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors.
Endo M; Yamamoto H; Setsu N; Kohashi K; Takahashi Y; Ishii T; Iida K; Matsumoto Y; Hakozaki M; Aoki M; Iwasaki H; Dobashi Y; Nishiyama K; Iwamoto Y; Oda Y
Clin Cancer Res; 2013 Jan; 19(2):450-61. PubMed ID: 23209032
[TBL] [Abstract][Full Text] [Related]
57. Knockdown of HMGA2 regulates the level of autophagy via interactions between MSI2 and Beclin1 to inhibit NF1-associated malignant peripheral nerve sheath tumour growth.
Yang K; Guo W; Ren T; Huang Y; Han Y; Zhang H; Zhang J
J Exp Clin Cancer Res; 2019 May; 38(1):185. PubMed ID: 31053152
[TBL] [Abstract][Full Text] [Related]
58. The promise of signal transduction in genetically driven sarcomas of the nerve.
Kim A; Pratilas CA
Exp Neurol; 2018 Jan; 299(Pt B):317-325. PubMed ID: 28859862
[TBL] [Abstract][Full Text] [Related]
59. Oncologic outcomes of sporadic, neurofibromatosis-associated, and radiation-induced malignant peripheral nerve sheath tumors.
LaFemina J; Qin LX; Moraco NH; Antonescu CR; Fields RC; Crago AM; Brennan MF; Singer S
Ann Surg Oncol; 2013 Jan; 20(1):66-72. PubMed ID: 22878618
[TBL] [Abstract][Full Text] [Related]
60. Characterization of the somatic mutational spectrum of the neurofibromatosis type 1 (NF1) gene in neurofibromatosis patients with benign and malignant tumors.
Upadhyaya M; Han S; Consoli C; Majounie E; Horan M; Thomas NS; Potts C; Griffiths S; Ruggieri M; von Deimling A; Cooper DN
Hum Mutat; 2004 Feb; 23(2):134-146. PubMed ID: 14722917
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
